Yes, HiB vaccine can and should be given concurrently with DPT and OPV
The Haemophilus influenzae type b (Hib) vaccine is safe and effective when administered at the same visit as DPT and OPV vaccines in healthy infants. This is standard practice supported by both FDA-approved labeling and current CDC guidelines 1, 2.
Evidence Supporting Concurrent Administration
Guideline Recommendations
The CDC explicitly endorses concurrent administration of these vaccines as part of routine infant immunization schedules 1. The combination approach is designed to:
- Reduce the number of clinic visits and injections
- Improve vaccination coverage and compliance
- Optimize disease prevention during the critical early months of life
FDA-Approved Practice
The FDA drug label for PedvaxHIB (a monovalent Hib vaccine) specifically states that "DTP and OPV were administered concomitantly to most subjects" in clinical trials 2. This concurrent administration was:
- Well tolerated with no serious vaccine-related adverse reactions
- Highly immunogenic across all age groups studied
- Effective in preventing invasive Hib disease even in high-risk populations
Combination Vaccine Options
Modern practice has evolved to include hexavalent combination vaccines that merge these antigens into a single injection. The DTaP-IPV-Hib-HepB vaccine (Vaxelis) is licensed for use at ages 2,4, and 6 months, combining all these components plus hepatitis B 1.
Clinical Implementation
Standard Schedule
- Primary series: Administer at 2,4, and 6 months of age
- Booster dose: Give Hib booster at 12-15 months (note: hexavalent vaccines should NOT be used for booster doses) 1
Important Considerations
Minimum intervals must be maintained 1:
- Minimum age for any dose: 6 weeks
- Minimum interval between doses: 4 weeks
- For hexavalent vaccines, minimum age for dose 3 is 24 weeks
Special populations: American Indian/Alaska Native infants have historically been at higher risk for invasive Hib disease. For these infants, PRP-OMP-containing vaccines (either monovalent PedvaxHIB or DTaP-IPV-Hib-HepB) are preferred because they provide substantial protection after the first dose 3.
Safety Profile
Research demonstrates that concurrent administration is well tolerated 4, 5. In large clinical trials:
- No serious vaccine-related adverse reactions were reported when vaccines were given together 2
- Minor local reactions (injection site erythema, swelling) and systemic reactions (fever, irritability) were comparable to rates seen with individual vaccines 2
- Seizures occurred infrequently and were not attributed to the Hib vaccine 2
Immunogenicity Considerations
Potential Interference
One important caveat: If using inactivated poliovirus vaccine (IPV) instead of OPV, there may be some reduction in anti-PRP (Hib) antibody response when given concurrently with combined DTaP/Hib vaccines 6. However:
- This interference is primarily relevant for combined DTaP/Hib formulations given with IPV
- The clinical significance is limited, as most children still achieve protective antibody levels
- This does not contraindicate concurrent administration 5
Overall Response
Studies confirm that concurrent administration of Hib with DTP and OPV produces adequate antibody responses to all antigens 4, 7. The antibody levels achieved are:
95% of infants achieve protective anti-PRP levels (≥0.15 mcg/mL) after the primary series 2
- Responses to diphtheria, tetanus, pertussis, and polio antigens remain robust 4, 5
Practical Guidance
Give all three vaccines at the same visit - there is no medical reason to separate them. The benefits of concurrent administration (improved compliance, timely protection) far outweigh any theoretical concerns about immune interference.
Use separate injection sites if giving individual vaccines rather than a combination product.
Do not delay vaccination if a specific vaccine product is unavailable - vaccines from different manufacturers can be interchanged, though using the same manufacturer's product throughout the series is preferred when feasible 1, 2.